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Abstract Metallothionein-3 (MT-3) has been shown to be
expressed in several malignancies and to have an impact on
patients’ survival in breast and urinary bladder cancer cases.
However, its expression has not been determined in normal
skin or in its malignant lesions. MT-3 expression was studied
using immunohistochemistry in 17 cases of normal skin, 18 of
actinic keratosis (AK), 39 of squamous cell carcinoma (SCC),
and 23 of basal cell carcinoma (BCC). Low MT-3 expression
was observed in normal skin epidermis with faint or no
expression in the epidermis basal layer. Significantly higher
MT-3 expression was noted in AK (P=0.007) and SCC
(P<0.0001), as compared with normal skin epidermis. BCC
cases were characterized by the lowest MT-3 expression of all
the examined groups, which was significantly lower in com-
parison to normal skin epidermis, AK, and SCC (P=0.009;
P<0.0001 and P<0.0001, respectively). In conclusion, MT-3
may be involved in the development of SCC.
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Introduction
Nonmelanoma skin cancer (NMSC) is the most frequent form
of neoplastic disease in Caucasian populations [1]. Since the
1960s, its overall incidence has increased by approximately 3–
8 % per year [1, 2]. NMSCs are mainly represented by two
histological tumor types: basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC) [1, 3]. Although BCC is seen
up to five times more frequently in patients, it is considered to
be an exclusively local malignant tumor due to the fact that
metastases (to lymph nodes and other organs) are rarely ob-
served [1, 4, 5]. However, SCC is considered a malignant skin
tumor and is responsible for the majority of NMSC associated
deaths [3]. Almost 80 % of all BCCs arise on sun-exposed
skin, developing mainly on the head and neck regions [4, 5]. It
has been shown that SCCmay develop either from a precursor
lesion, such as actinic keratosis (AK), or de novo. Although it
is thought that a significant fraction of SCCs evolve from AK,
the potential of malignant transformation cannot be predicted
from clinical characteristics and is difficult to assess [3].
Unlike SCCs, BCCs do not have precursor lesions and instead
appear de novo as a tumor which can usually be classified into
one of two main groups: nodular BCCs are the most common,
presenting as a small pearly papule with well-developed pe-
ripheral cells palisading. Superficial BCCs macroscopically
manifest as scaly erythematous plaques and buds of atypical
basal cells arising from the basal layer of epidermis [5, 6]. The
abovementioned forms manifest low aggressiveness and may
often be cured through local excision, however also histopath-
ological BCC types of higher aggressiveness and frequent
local recurrences are distinguished e.g. micronodular,
morpheaform, infiltrative and metatypic types [5, 6].
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Metallothioneins (MTs) are a family of small (6–7 kDa),
intracellular, nonenzymatic family of proteins that are highly
conserved among species [7]. MTs are characterized by high
cysteine content in their polypeptide chain [8]. The high
number of thiol (−SH) groups enables them to bind metals,
such as Zn, Cd, Cu, and Hg, and to transfer Cu and Zn to the
catalytic sites of various enzymes [9, 10]. MTs are encoded by
a family of genes located on human chromosome 16q13, and
four main groups of these proteins can be distinguished (MT-
1, MT-2, MT-3, MT-4) [11]. Lines of evidence suggest that
MT-1 and MT-2 play important roles in various cellular pro-
cesses—in both normal and cancer cells—such as detoxifica-
tion of heavy metals, homeostasis of zinc and copper ions, and
protection of cell DNA against oxidative stress damage, pro-
liferation, and apoptosis [7, 8, 10, 12–14]. Elevated MT-1/2
expression has been associated with poor patient prognosis in
ovarian, renal, lung, and colorectal cancer, as well in soft
tissue sarcomas [12, 15–20]. Although numerous studies have
been performed on the role of MT-1/2 isoforms in various
normal and pathological processes, little is known yet regard-
ing the role of metallothionein-3 (MT-3) in cancer cells.
MT-3 was first identified in rat brain extracts in the
course of Alzheimer’s disease and possesses an unique
neuronal cell growth inhibitory property, not exerted by
other members of the family, (such as MT-1/2) [21]. On
account of this property, MT-3 was first described as a
growth-inhibitory factor (GIF) [21, 22]. Its expression
was initially reported to be very restricted to the ner-
vous tissues, but further studies proved its wider distri-
bution in the human body [22–28]. The results of recent
research concerning the role of MT3 in neoplastic dis-
eases remain ambiguous and are frequently inconsistent.
It has been shown that, in human bladder, breast, and
prostate cancer, the expression of MT-3 increases [22,
24, 27]. On the contrary, in esophageal squamous cell
cancer and adenocarcinoma of the esophagus—as well
as in gastric cancer—MT-3 expression decreases, as
compared with normal tissue [23, 29, 30]. Although
the expression of MT-1/2 has been intensively studied
in normal and malignant skin lesions, no information
concerning MT-3 expression is currently available [31,
32]. It has been shown that MT-1/2 expression increases
significantly with the progression from normal skin to
AK, with the highest expression noted for SCC [32].
Moreover, MT-1/2 has been shown to be positively
correlated with Ki-67 antigen expression in AK, SCC,
and BCC—confirming its role in regulation of cell
proliferation [31, 32].
Taking into account that MT-1/2 may have an impact on
carcinogenic processes in the skin, we analyzed the expression
of MT-3 using immunohistochemical methods in cases of
normal skin, AK, SCC, and BCC, with regard to the clinical
and pathological characteristics of patients.
Material and Methods
Patients and Tissue Samples
The study was performed on tissue samples obtained from
patients during the resection of skin lesions due to suspicion of
clinical cancer in the Department and Clinic of Dermatology,
Venereology, and Allergology, Medical University of
Wroclaw. The study group consisted of 97 skin samples, of
which 17 were diagnosed as normal skin, 18 as AK, 39 as
SCC and, 23 as BCC (12 of the nodular type and 11 of the
superficial type).
Resected tissue samples were fixed in 10 % buffered for-
malin and embedded in paraffin following prior dehydration.
Six micrometer-thick sections were evaluated independently
by two pathologists to verify the diagnosis and to assess the
clinical and pathological characteristics of the analyzed SCC
cases. The four-grade Broders scale classifies the differentia-
tion and keratinization of tumor cells, and was employed here
to determine the malignancy grade of the studied SCC tumors
[33]. It is encoded as follows: G1 (>75 % keratinized cells),
G2 (50–75 % keratinized cells), G3 (25–50 % keratinized
cells), and G4 (<25 % keratinized cells). In addition, the
degree of keratinization and the depth of inflammatory infil-
trate were assessed. The mean patient age was 72.5±13.2
(range 37 to 97) years. The clinical and pathological data of
the SCC patients are summarized in Table 1.
Immunohistochemistry (IHC)
For IHC reactions, four micrometer-thick sections were fresh-
ly cut and deparaffinized in xylene with subsequent rehydra-
tion in alcohol (absolute, 96 %, 70 %), with 5 min’ incubation
each. Sections were boiled for 20 min in Target Retrieval
Buffer (high pH for MT-3 and low pH for Ki-67 antigen)
using a PT Link (Pre-Treatment Module for Tissue
Specimens), in order to retrieve the studied antigens. Sections
were then rinsed in TBS buffer with 0.05 % Tween. Then the
EnVision™ FLEX Detection System was employed. EnVi-
sion™ FLEX Peroxidase-Blocking Reagent was used to
block endogenous peroxidase, with 5 min’ incubation. Fol-
lowing rinsing in TBS with 0.05 % Tween, the primary
antibodies were applied: anti-MT-3, a rabbit polyclonal anti-
body raised against GGEAAEAEAEKC peptide (1:200,
Invitrogen, Carlsbad, California, USA) and anti-Ki-67 (ready
to use, Dako Cytomation, Glostrup, Denmark). Following
20 min of incubation, the slides were rinsed in TBS with
0.05 % Tween, and the secondary antibody conjugated with
horseradish peroxidase was used (EnVision™ FLEX/HRP),
with incubation for 20 min. The MT-3 and Ki-67 reaction was
visualized using freshly prepared substrate for horseradish
peroxidase (diaminobenzidine, EnVision™ Working Solu-
tion), with incubation for 10 min. Additionally, all slides were
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counterstained using EnVision™ FLEX Hematoxylin and
5 min’ incubation. Eventually, after dehydration in graded
ethanol concentrations (70 %, 96 %, absolute) and in xylene,
all slides were closed with coverslips in SUB-X Mounting
Medium in Coverslipper. All reagents and equipment, except
for the MT-3 antibody, were purchased from Dako
Cytomation.
Evaluation of IHC Reactions
All IHC reactions were assessed using a BX41 light micro-
scope (Olympus, Tokyo, Japan) independently by two pathol-
ogists, who were blinded to patient clinico-pathological data.
In case of discrepancy between the pathologist, the staining
was discussed until a consensus has been achieved. The
expression intensity of MT-3 in the tumor cells was evaluated
using the semi-quantitative 12-point immunoreactive score
(IRS) of Remmele and Stegner, utilized previously in our
studies concerning MT1/2 expression [31, 34]. The cytoplas-
mic MT3 IRS reaction score was calculated in each case,
taking into account both the percentage of positive cells (0
points: no cells with positive reaction; 1 point: 1–10% cells; 2
points: 11–50 %; 3 points: 51–80 %; 4 points: over 80 % cells
with positive reaction) and the intensity of the reaction (0: no
reaction; 1: low intensity of the reaction color; 2: moderate
intensity of the reaction color; 3: intense color of the reaction).
The final score represents the product of these two parameters
and ranges from 0 to 12 points.
The expression of Ki-67 antigen in healthy skin and its
lesions was assessed by the proportion of positive cells from
all epidermal (normal skin and AK) or tumor cells (BCC and
SCC) in whole tissue sections, and was coded as follows: 0
points for no reaction, 1 point for 1–10 %, 2 points for 11–
25 %, 3 points for 26–50 %, and 4 points for>50 % positive
cells.
Statistical Analysis
The results were subjected to statistical analysis using Prism
5.0 (GraphPad Software, La Jolla, CA, USA). The Shapiro-
Wilk test was employed to test the distribution. Mann-
Whitney’s U-test was used to assess the differences in MT-3
expression between the two groups. The correlation between
the expression intensity of the selected markers was evaluated
using the Spearman correlation test, or the Pearson test in the
case of patient age analyses. The results were regarded as
statistically significant for P<0.05.
Results
A cytoplasmic reaction in MT-3 immunostained slides was
observed in 89 (91.8 %) of all analyzed cases. No staining was
noted in the remaining 8 (8.2 %) cases (Fig. 1), one of which
involved normal healthy skin and seven of which involved
BCC. No nuclear MT-3 expression pattern could be seen in
the keratinocytes of normal skin epidermis, AK, or in the
tumor cells of BCC and SCC. MT-3 expression was mostly
noted in the suprabasal layer of the epidermis in normal skin
and AK lesions, with only scant faint expression noted in the
basal layer (Fig. 1).
Low MT-3 expression level was observed in normal skin
epidermis, scoring at the average of 2.65 (SD±1.69) on the
IRS scale. A significantly higher MT-3 expression was noted
in AK (IRS 4.61±2.36; P=0.007) and SCC (IRS 6.15±2.35;
P<0.0001), as compared with normal skin epidermis. The
BCC cases were characterized by the lowest intensity of
MT-3 expression of all the examined groups (IRS 1.30±
1.11), being significantly lower in comparison to normal skin
epidermis, AK, and SCC (P=0.009; P<0.0001 and
P<0.0001, respectively) (Fig. 2).
Nuclear expression of Ki-67 antigen was observed in all of
the analyzed cases. Its expression was lowest in healthy skin
epidermis (1.18±0.64), and was significantly lower than in the
cases of BCC (2.16±0.92; P=0.006), AK (2.17±0.92; P=
0.002), and SCC (2.02±1.06; P=0.0062) (Fig. 3).
The statistical analysis of MT-3 expression in SCC cases
did not reveal any significant differences in SCC as regarding
patient age (Pearson correlation test), sex, depth of inflamma-
tory infiltration, malignancy grade, differentiation (keratotic
vs. akeratotic), or sun exposure (Mann–Whitney test, respec-
tively). Similar results were observed for Ki-67 antigen ex-
pression. Moreover, no significant correlation was noted
Table. 1 Patient and tumor characteristics of the squamous cell carcino-
ma cases analyzed
Parameter No. of cases (%)
Sex
Male 22 (56.4 %)
Female 17 (44.6 %)
Differentiation
Keratotic 31 (79.5 %)
Akeratotic 8 (20.5 %)
Broders scale
G1 7 (17.9 %)
G2 10 (25.7 %)
G3 14 (35.9 %)
G4 8 (20.5 %)
Depth of inflammatory infiltration
Epidermis 9 (23.1 %)
Subcutaneous tissue 30 (76.9 %)
Sun exposure
Exposed 36 (92.3 %)
Occulted 3 (7.7 %)
MT-3 expression in skin cancer 189
between MT-3 and Ki-67 antigen expression in normal skin
and its lesions (BCC, AK, SCC; Spearman correlation test).
Discussion
The MT-3 gene was first identified by Palmiter et al., and
initial studies demonstrated that MT-3 expression was limited
mainly to neuronal tissue [35, 36]. Nevertheless, recent re-
search has revealed a broader physiological distribution of the
molecule not only in normal tissue, but also in human prostate,
esophagus, breast, and non-small-cell lung cancers [24, 25,
28, 37, 38]. Although MT-3 expression has been identified in
cancer cells, its exact role in oncological diseases requires
further clarification. Augmented MT-3 expression was ob-
served in neoplastic cells of breast, prostate, bladder, and
non-small-cell lung cancer [22, 24, 27, 38]. In contrast, in
human esophageal cancers and gastric cancer, MT-3 expres-
sion has been seen to be frequently downregulated due to the
increased DNA methylation in comparison with nonmalig-
nant tissues of these organs [23, 29, 30].
Fig. 1 Cytoplasmic
metallothionein-3 expression (a)
in healthy skin epidermis, (b) in
actinic keratosis, (c) in squamous
cell carcinoma, and (d) in basal
cell carcinoma. Magnification×
200
Fig. 2 Differentiated cytoplasmic metallothionein-3 (MT-3) expression
with regard to the type of analyzed sample. * P<0.05; ** P<0.005; ***
P<0.0005; **** P<0.0001 (Mann–Whitney test); AK: actinic keratosis;
BCC: basal cell carcinoma; SCC: squamous cell carcinoma
Fig. 3 Nuclear Ki-67 antigen expression in regard to the type of analyzed
sample. ** P<0.005; *** P<0.0005 (Mann–Whitney test); AK: actinic
keratosis; BCC: basal cell carcinoma; SCC: squamous cell carcinoma
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In this study, we demonstrated for the first time MT-3
expression in normal skin keratinocytes. Additionally, its ex-
pression seems to be associated with the stratification of the
epithelium, as cells in the basal layer are characterized by
lowerMT-3 expression levels (including zero expression) than
in the case of the more differentiated cells of the suprabasal
layers. Similar results have been obtained in regard to MT-4
[39]. In contrast, MT-1 and MT-2 probably exhibit different
paths of expression and regulation, as less differentiated and
undifferentiated cells from the basal layer demonstrate higher
expression, as compared to suprabasal layers of keratinocytes
[32].
Actinic keratosis is considered a premalignant skin lesion
that can evolve to SCC [3, 32]. The observation of changes in
the MT-3 expression intensity in normal skin epidermis, AK,
and SCC point to the potential role of this protein in skin
carcinogenesis. AK cases exhibit an intermediate MT-3 ex-
pression, which is higher in comparison to that noted in
normal skin epidermis, but lower when compared to that of
SCC cancer cells. Similar results regarding MT-1/2 were
obtained by Zamirska et al., in whose work SCC cases were
characterized by higher expression in AK, with the lowest
expression in normal skin epidermis [32]. This observation
may indicate the role of MT-3 in the development of SCC.
Interestingly, we have also observed different intensities of its
expression in cases of BCC and SCC, as significantly higher
MT-3 expression was observed in the latter NMSC type. This
observation is also consistent with the MT-3 expression pat-
tern noted in healthy skin and AK lesions, in which only a
scant, faint expression was visible in the basal cells. It is
possible that MT-3 expression in BCC and basal cells may
be the result of similar regulation processes based on DNA
methylation, as has been observed in gastric and esophageal
cancers [23, 30]. On the other hand, keratinocytes of the
suprabasal layers are characterized by higher levels of MT-3
expression, which increases with the malignant potential of
the lesion, the peak being achieved in SCC. These observa-
tions may be partially clarified by the regulation of zinc ion
homeostasis in healthy and malignant skin lesions. Zinc ions
have been shown to mediate numerous processes in skin
biology, ranging from keratinocyte differentiation, through
wound healing, to cancer development [40, 41]. Moreover,
zinc deficiency was frequently present in patients with squa-
mous cell carcinomas diagnosed in oral cavity, oropharynx
and larynx [42]. MTs have been shown to regulate zinc ion
homeostasis in response to stress, and therefore might serve as
a key source of the exchangeable zinc ions needed for regu-
lating transcription factor activity, and ultimately, diverse cel-
lular response signals in SCC cancer cells [8, 43]. Although no
studies have focused on revealing the relationship of MT-3
with metal ion homeostasis, this path in the carcinogenesis of
the skin remains to be clarified. In this study we aimed at
defining the role of MT-3 in the regulation of cellular
proliferation, which was assessed in this study by examining
the expression intensity of the Ki-67 antigen. However, no
correlation between those two markers could be disclosed,
indicating that MT-3 may probably impact other cellular pro-
cess than proliferation in skin lesions. Recently, MT-3 was
shown to be involved in the regulation of lysosomal
function and autophagy in neurons and astrocytes, and
may also potentially influence this processes during skin
carcinogenesis [44, 45]. To our knowledge, the exact
role of MT-3 expression in regard to autophagic pro-
cesses in cancer cells has not yet been investigated. MT-
3 was also shown to protect neurons from hypoxia or
DNA-induced damage via increased activity of NF-κB
and protein kinase B (Akt) signaling pathway [46]. This
may also be one of potential mechanism of actions of
MT-3, as it was shown that Akt is overexpressed in
SCC [47].
In our study, we did not observe any significant relation-
ship between MT-3 expression in SCC cancer cells and any
clinical and pathological parameters that might point to the
role of MT-3 in SCC progression and prognosis. Our results
are comparable to those obtained during the examination of
esophageal and gastric cancers, where MT-3 expression had
no impact on patients’ clinical or pathological data or on
patient survival [23, 29, 30]. However, in the study of Sens
et al., MT-3 expression was up-regulated in human bladder
cancer tumor cells, and was positively correlated with the
tumor malignancy grade [27]. In addition, in breast cancer,
MT-3 expression is considered to be a marker of poor prog-
nosis [22, 37]. Although, we did not notice any correlations
between MT-3 expression intensity in cancer cells and SCC
patients clinico-pathological data, the prognostic impact of
MT-3 expression remains to be yet determined. In the current
study we had no information concerning the survival time of
SCC patients, therefore we could not definitely define the
potential utility of MT-3 as a new prognostic marker of this
malignancy.
In summary, we have shown for the first time that MT-3
may be potentially involved in the development of SCC.
Moreover, the varying expression levels of MT-3 observed
by us in SCC and BCC confirm the differing biology of both
these malignant skin lesions.
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